{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:52:53Z","timestamp":1791928373240,"version":"4.3.4"},"reference-count":84,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":162,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["DK025636"],"award-info":[{"award-number":["DK025636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:p>Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an impairment or disruption of bile production and causes intracellular retention of toxic bile constituents, including bile salts. If left untreated, cholestasis leads to liver fibrosis and cirrhosis, which eventually results in liver failure and the need for liver transplantation. Currently, the only therapeutic option available for these patients is ursodeoxycholic acid (UDCA), which slows the progression of PBC, particularly in stage I and II of the disease. However, some patients have an incomplete response to UDCA therapy, whereas other, more advanced cases often remain unresponsive. For PSC, UDCA therapy does not improve survival, and recommendations for its use remain controversial. These considerations emphasize the need for alternative therapies. Hepatic transporters, located along basolateral (sinusoidal) and apical (canalicular) membranes of hepatocytes, are integral determinants of bile formation and secretion. Nuclear receptors (NRs) are critically involved in the regulation of these hepatic transporters and are natural targets for therapy of cholestatic liver diseases. One of these NRs is peroxisome proliferator\u2010activated receptor alpha (PPAR\u03b1), which plays a central role in maintaining cholesterol, lipid, and bile acid homeostasis by regulating genes responsible for bile acid synthesis and transport in humans, including cytochrome P450 (CYP) isoform 7A1 (CYP7A1), CYP27A1, CYP8B1, uridine 5'\u2010diphospho\u2010glucuronosyltransferase 1A1, 1A3, 1A4, 1A6, hydroxysteroid sulfotransferase enzyme 2A1, multidrug resistance protein 3, and apical sodium\u2010dependent bile salt transporter. Expression of many of these genes is altered in cholestatic liver diseases, but few have been extensively studied or had the mechanism of PPAR\u03b1 effect identified. In this review, we examine what is known about these mechanisms and consider the rationale for the use of PPAR\u03b1 ligand therapy, such as fenofibrate, in various cholestatic liver disorders. (H<jats:sc>epatology<\/jats:sc> 2015;62:635\u2013643<\/jats:p>","DOI":"10.1002\/hep.27744","type":"journal-article","created":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T04:09:27Z","timestamp":1423800567000},"page":"635-643","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":294,"title":["Fibrates and cholestasis"],"prefix":"10.1097","volume":"62","author":[{"given":"Nisanne S.","family":"Ghonem","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences,School of Pharmacy, MCPHS University,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Assis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine,Liver Center, Yale University School of Medicine,New Haven,CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Boyer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine,Liver Center, Yale University School of Medicine,New Haven,CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2015,3,23]]},"reference":[{"key":"hep27744-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1053\/j.gastro.2010.09.004","article-title":"Pathogenesis of cholestatic liver disease and therapeutic approaches","volume":"139","year":"2010","journal-title":"Gastroenterology"},{"key":"hep27744-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1152\/physrev.00027.2002","article-title":"Bile salt transporters: molecular characterization, function, and regulation","volume":"83","year":"2003","journal-title":"Physiol Rev"},{"key":"hep27744-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/hep.1840140324","article-title":"Mechanisms and regulation of bile secretion","volume":"14","year":"1991","journal-title":"Hepatology"},{"key":"hep27744-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1172\/JCI117658","article-title":"Regulation of biliary lipid secretion by mdr2 P\u2010glycoprotein in the mouse","volume":"95","year":"1995","journal-title":"J Clin Invest"},{"key":"hep27744-bib-0005-20241017","first-page":"2029","article-title":"Identification of a sister gene to P\u2010glycoprotein","volume":"55","year":"1995","journal-title":"Cancer Res"},{"key":"hep27744-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1172\/JCI0216001","article-title":"Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol","volume":"110","year":"2002","journal-title":"J Clin Invest"},{"key":"hep27744-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1096\/fasebj.11.1.9034162","article-title":"Hepatic canalicular membrane 1: the role of mdr2 P\u2010glycoprotein in hepatobiliary lipid transport","volume":"11","year":"1997","journal-title":"FASEB J"},{"key":"hep27744-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/3034","article-title":"A gene encoding a liver\u2010specific ABC transporter is mutated in progressive familial intrahepatic cholestasis","volume":"20","year":"1998","journal-title":"Nat Genet"},{"key":"hep27744-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1055\/s-0030-1253223","article-title":"The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects","volume":"30","year":"2010","journal-title":"Semin Liver Dis"},{"key":"hep27744-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/347645a0","article-title":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators","volume":"347","year":"1990","journal-title":"Nature"},{"key":"hep27744-bib-0011-20241017","first-page":"649","article-title":"Peroxisome proliferator\u2010activated receptors: nuclear control of metabolism","volume":"20","year":"1999","journal-title":"Endocr Rev"},{"key":"hep27744-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.tox.2007.09.030","article-title":"PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators","volume":"246","year":"2008","journal-title":"Toxicology"},{"key":"hep27744-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1128\/MCB.00317-07","article-title":"Peroxisome proliferator\u2010activated receptor alpha regulates a microRNA\u2010mediated signaling cascade responsible for hepatocellular proliferation","volume":"27","year":"2007","journal-title":"Mol Cell Biol"},{"key":"hep27744-bib-0014-20241017","first-page":"665","article-title":"PPAR alpha, fibrates, lipid metabolism and inflammation","volume":"97","year":"2004","journal-title":"Arch Mal Coeur Vaiss"},{"key":"hep27744-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI6223","article-title":"Peroxisome proliferator\u2010activated receptor alpha mediates the adaptive response to fasting","volume":"103","year":"1999","journal-title":"J Clin Invest"},{"key":"hep27744-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","year":"2000","journal-title":"J Med Chem"},{"key":"hep27744-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0960-0760(91)90191-7","article-title":"Cloning of novel members of the steroid hormone receptor superfamily","volume":"40","year":"1991","journal-title":"J Steroid Biochem Mol Biol"},{"key":"hep27744-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/clpt.2011.124","article-title":"Profile of serum bile acids in noncholestatic volunteers: gender\u2010related differences in response to fenofibrate","volume":"90","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"hep27744-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/hq1101.098228","article-title":"Fibrates suppress bile acid synthesis via peroxisome proliferator\u2010activated receptor\u2010alpha\u2010mediated downregulation of cholesterol 7alpha\u2010hydroxylase and sterol 27\u2010hydroxylase expression","volume":"21","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"hep27744-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0022-2275(20)32398-1","article-title":"Peroxisome proliferator\u2010activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha\u2010hydroxylase gene (CYP7A1) transcription","volume":"41","year":"2000","journal-title":"J Lipid Res"},{"key":"hep27744-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"28947","DOI":"10.1074\/jbc.M002782200","article-title":"The peroxisome proliferator\u2010activated receptor alpha (PPARalpha) regulates bile acid biosynthesis","volume":"275","year":"2000","journal-title":"J Biol Chem"},{"key":"hep27744-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/mol.112.082503","article-title":"Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator\u2010activated receptor alpha (PPARalpha)","volume":"83","year":"2013","journal-title":"Mol Pharmacol"},{"key":"hep27744-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"32852","DOI":"10.1074\/jbc.M305361200","article-title":"Peroxisome proliferator\u2010activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP\u2010glucuronosyltransferase 2B4 enzyme","volume":"278","year":"2003","journal-title":"J Biol Chem"},{"key":"hep27744-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/dmd.106.013243","article-title":"Expression of the human UGT1 locus in transgenic mice by 4\u2010chloro\u20106\u2010(2,3\u2010xylidino)\u22122\u2010pyrimidinylthioacetic acid (WY\u201014643) and implications on drug metabolism through peroxisome proliferator\u2010activated receptor alpha activation","volume":"35","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"hep27744-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/mol.104.005389","article-title":"Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator\u2010activated receptor alpha transcription factor","volume":"67","year":"2005","journal-title":"Mol Pharmacol"},{"key":"hep27744-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"30559","DOI":"10.1074\/jbc.M203511200","article-title":"Human apical sodium\u2010dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator\u2010activated receptor alpha","volume":"277","year":"2002","journal-title":"J Biol Chem"},{"key":"hep27744-bib-0027-20241017","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1194\/jlr.M027433","article-title":"Metabolomics reveals an essential role for peroxisome proliferator\u2010activated receptor alpha in bile acid homeostasis","volume":"53","year":"2012","journal-title":"J Lipid Res"},{"key":"hep27744-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"17838","DOI":"10.1074\/jbc.M210634200","article-title":"Protective role of hydroxysteroid sulfotransferase in lithocholic acid\u2010induced liver toxicity","volume":"278","year":"2003","journal-title":"J Biol Chem"},{"key":"hep27744-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1146\/annurev.ge.29.120195.003135","article-title":"Genetic analysis of the multidrug transporter","volume":"29","year":"1995","journal-title":"Annu Rev Genet"},{"key":"hep27744-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(93)90380-9","article-title":"Homozygous disruption of the murine mdr2 P\u2010glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease","volume":"75","year":"1993","journal-title":"Cell"},{"key":"hep27744-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1053\/gast.2002.35948","article-title":"Ursodeoxycholic acid aggravates bile infarcts in bile duct\u2010ligated and Mdr2 knockout mice via disruption of cholangioles","volume":"123","year":"2002","journal-title":"Gastroenterology"},{"key":"hep27744-bib-0032-20241017","doi-asserted-by":"crossref","first-page":"G670","DOI":"10.1152\/ajpgi.00334.2013","article-title":"Altered expression and function of canalicular transporters during early development of cholestatic liver injury in Abcb4\u2010deficient mice","volume":"306","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"hep27744-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s10354-008-0592-1","article-title":"Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases","volume":"158","year":"2008","journal-title":"Wien Med Wochenschr"},{"key":"hep27744-bib-0034-20241017","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0026-0495(93)90056-T","article-title":"The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities","volume":"42","year":"1993","journal-title":"Metabolism"},{"key":"hep27744-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/hep.26155","article-title":"Fibrates as adjuvant therapy for chronic cholestatic liver disease\u2014it's time has come","volume":"57","year":"2013","journal-title":"Hepatology"},{"key":"hep27744-bib-0036-20241017","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid","volume":"57","year":"2013","journal-title":"Hepatology"},{"key":"hep27744-bib-0037-20241017","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.26894","article-title":"Peroxisome proliferator\u2010activated receptor alpha activates human multidrug resistance transporter 3\/ATP\u2010binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion","volume":"59","year":"2014","journal-title":"Hepatology"},{"key":"hep27744-bib-0038-20241017","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1194\/jlr.M400132-JLR200","article-title":"Bezafibrate stimulates canalicular localization of NBD\u2010labeled PC in HepG2 cells by PPARalpha\u2010mediated redistribution of ABCB4","volume":"45","year":"2004","journal-title":"J Lipid Res"},{"key":"hep27744-bib-0039-20241017","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1042\/bj20020981","article-title":"Peroxisome proliferator\u2010activated receptor alpha (PPARalpha)\u2010mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice","volume":"369","year":"2003","journal-title":"Biochem J"},{"key":"hep27744-bib-0040-20241017","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1042\/bj3140781","article-title":"Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse","volume":"314","year":"1996","journal-title":"Biochem J"},{"key":"hep27744-bib-0041-20241017","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hep.21158","article-title":"Mrp4\u2010\/\u2010 mice have an impaired cytoprotective response in obstructive cholestasis","volume":"43","year":"2006","journal-title":"Hepatology"},{"key":"hep27744-bib-0042-20241017","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.24801","article-title":"Elevated hepatic multidrug resistance\u2010associated protein 3\/ATP\u2010binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c\u2010Jun NH2\u2010terminal kinase\/stress\u2010activated protein kinase\u2010signaling pathway","volume":"55","year":"2012","journal-title":"Hepatology"},{"key":"hep27744-bib-0043-20241017","doi-asserted-by":"crossref","first-page":"36703","DOI":"10.1074\/jbc.M004045200","article-title":"Induction of IkappaBalpha expression as a mechanism contributing to the anti\u2010inflammatory activities of peroxisome proliferator\u2010activated receptor\u2010alpha activators","volume":"275","year":"2000","journal-title":"J Biol Chem"},{"key":"hep27744-bib-0044-20241017","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1161\/01.CIR.99.24.3125","article-title":"PPARalpha activators inhibit cytokine\u2010induced vascular cell adhesion molecule\u20101 expression in human endothelial cells","volume":"99","year":"1999","journal-title":"Circulation"},{"key":"hep27744-bib-0045-20241017","doi-asserted-by":"crossref","first-page":"51085","DOI":"10.1074\/jbc.M308321200","article-title":"Farnesoid X receptor activates transcription of the phospholipid pump MDR3","volume":"278","year":"2003","journal-title":"J Biol Chem"},{"key":"hep27744-bib-0046-20241017","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","year":"2000","journal-title":"Cell"},{"key":"hep27744-bib-0047-20241017","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1210\/me.2002-0120","article-title":"Bile acids induce the expression of the human peroxisome proliferator\u2010activated receptor alpha gene via activation of the farnesoid X receptor","volume":"17","year":"2003","journal-title":"Mol Endocrinol"},{"key":"hep27744-bib-0048-20241017","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/S0016-5085(03)00388-3","article-title":"FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity","volume":"124","year":"2003","journal-title":"Gastroenterology"},{"key":"hep27744-bib-0049-20241017","first-page":"912","article-title":"Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group","volume":"81","year":"1998","journal-title":"Am J Cardiol"},{"key":"hep27744-bib-0050-20241017","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0022-2275(20)42003-6","article-title":"Role of the peroxisome proliferator\u2010activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression","volume":"37","year":"1996","journal-title":"J Lipid Res"},{"key":"hep27744-bib-0051-20241017","first-page":"539","article-title":"Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia","volume":"33","year":"1987","journal-title":"Drugs"},{"key":"hep27744-bib-0052-20241017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1386-6346(99)00033-9","article-title":"Benzafibrate may have beneficial effect in pre\u2010cirrhotic primary biliary cirrhosis","volume":"16","year":"1999","journal-title":"Hepatol Res"},{"key":"hep27744-bib-0053-20241017","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00535-004-1518-3","article-title":"Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis","volume":"40","year":"2005","journal-title":"J Gastroenterol"},{"key":"hep27744-bib-0054-20241017","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MCG.0b013e3181c115b3","article-title":"Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid","volume":"44","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"hep27744-bib-0055-20241017","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study","volume":"38","year":"2008","journal-title":"Hepatol Res"},{"key":"hep27744-bib-0056-20241017","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: a new medical approach for PBC patients?","volume":"38","year":"2003","journal-title":"J Gastroenterol"},{"key":"hep27744-bib-0057-20241017","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00535-006-1831-0","article-title":"Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels","volume":"41","year":"2006","journal-title":"J Gastroenterol"},{"key":"hep27744-bib-0058-20241017","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1572-0241.2002.05413.x","article-title":"Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy","volume":"97","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"hep27744-bib-0059-20241017","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1111\/j.1572-0241.2000.03220.x","article-title":"Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid","volume":"95","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"hep27744-bib-0060-20241017","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid","volume":"34","year":"2014","journal-title":"Liver Int"},{"key":"hep27744-bib-0061-20241017","first-page":"1518","article-title":"A novel treatment for refractory primary biliary cirrhosis?","volume":"47","year":"2000","journal-title":"Hepatogastroenterology"},{"key":"hep27744-bib-0062-20241017","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","article-title":"Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study","volume":"95","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"hep27744-bib-0063-20241017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1034\/j.1600-0676.2001.021003223.x","article-title":"Effect of bezafibrate in primary biliary cirrhosis: a pilot study","volume":"21","year":"2001","journal-title":"Liver"},{"key":"hep27744-bib-0064-20241017","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00535-006-1778-1","article-title":"Long\u2010term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis","volume":"41","year":"2006","journal-title":"J Gastroenterol"},{"key":"hep27744-bib-0065-20241017","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1440-1746.2011.06737.x","article-title":"Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid","volume":"26","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"hep27744-bib-0066-20241017","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1572-0241.2002.05645.x","article-title":"Is bezafibrate histologically effective for primary biliary cirrhosis?","volume":"97","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"hep27744-bib-0067-20241017","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","article-title":"Fenofibrate treatment in patients with primary biliary cirrhosis","volume":"97","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"hep27744-bib-0068-20241017","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"hep27744-bib-0069-20241017","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1751-2980.2012.00574.x","article-title":"Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy","volume":"13","year":"2012","journal-title":"J Dig Dis"},{"key":"hep27744-bib-0070-20241017","first-page":"350","article-title":"Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis","volume":"104","year":"2013","journal-title":"Fukuoka Igaku Zasshi"},{"key":"hep27744-bib-0071-20241017","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long\u2010term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"hep27744-bib-0072-20241017","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2146\/ajhp120131","article-title":"Fenofibrate\u2010associated nephrotoxicity: a review of current evidence","volume":"70","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"hep27744-bib-0073-20241017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2011.08.008","article-title":"Evaluation of the incidence and risk factors for development of fenofibrate\u2010associated nephrotoxicity","volume":"6","year":"2012","journal-title":"J Clin Lipidol"},{"key":"hep27744-bib-0074-20241017","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/eci.12068","article-title":"Fenofibrate and the kidney: an overview","volume":"43","year":"2013","journal-title":"Eur J Clin Invest"},{"key":"hep27744-bib-0075-20241017","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2337\/dc11-1109","article-title":"Benefits and safety of long\u2010term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study","volume":"35","year":"2012","journal-title":"Diabetes Care"},{"key":"hep27744-bib-0076-20241017","first-page":"407","article-title":"Possible mechanisms of the fibrate\u2010induced increase in serum creatinine","volume":"57","year":"2002","journal-title":"Clin Nephrol"},{"key":"hep27744-bib-0077-20241017","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","year":"2007","journal-title":"Am J Cardiol"},{"key":"hep27744-bib-0078-20241017","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-199834020-00003","article-title":"Clinical pharmacokinetics of fibric acid derivatives (fibrates)","volume":"34","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"hep27744-bib-0079-20241017","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.1990.03450010075034","article-title":"Myopathy and rhabdomyolysis associated with lovastatin\u2010gemfibrozil combination therapy","volume":"264","year":"1990","journal-title":"JAMA"},{"key":"hep27744-bib-0080-20241017","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0168-8278(11)60030-5","article-title":"An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC","volume":"54","year":"2011","journal-title":"J Hepatol"},{"key":"hep27744-bib-0081-20241017","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1517\/14656566.2014.873404","article-title":"Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis","volume":"15","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"hep27744-bib-0082-20241017","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","year":"2013","journal-title":"Gastroenterology"},{"key":"hep27744-bib-0083-20241017","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0002-9343(87)90868-0","article-title":"Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives","volume":"83","year":"1987","journal-title":"Am J Med"},{"key":"hep27744-bib-0086-20241017","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0016-5085(19)32419-9","article-title":"Effects of clofibrate in primary biliary cirrhosis hypercholesterolemia and gallstones","volume":"69","year":"1975","journal-title":"Gastroenterology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.27744","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201508000-00035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:49:57Z","timestamp":1729212597000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201508000-00035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,23]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.27744","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,23]]},"assertion":[{"value":"2014-10-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-01-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}